IDH1 and acute myeloid leukemia: Global methylation analysis also revealed a shared hypermethylation signature in a subset of AML patients carrying IDH1/2 mutations [52,134], a well-known TET2 inhibitor and mutually exclusive mutated gene (See Section 2.4).